Search

Memorial Sloan Kettering Cancer Center (MSK) today announced that Shelly Anderson, MPM, will join the institution as the inaugural Hospital President on September 25. Anderson joins MSK from Brigham and Women’s Hospital (BWH) in Boston, where she has been a member of the executive leadership team since 2011, most recently serving as Executive Vice President and Chief Operating Officer.

… Monday, June 26, 2023 Memorial Sloan Kettering Cancer Center (MSK) today announced that Shelly Anderson, MPM, will join the institution as the inaugural Hospital President on September 25. Anderson joins MSK from Brigham and Women’s Hospital (BWH) in Boston, where she has been a member of the executive

The event featured scientific talks from leading women in science, including winners of this year’s Kravis WISE fellowships.

… Friday, March 19, 2021 On March 17, 2021, scientists from around the world tuned in to watch the 2nd Annual Kravis WISE Symposium , a series of scientific talks sponsored by the Marie-Josée Kravis Women in Science Endeavor (WISE) at Memorial Sloan Kettering. Launched in 2020, Kravis WISE is devoted to

The Tri-Institutional Stem Cell Initiative, comprised of three leading New York City biomedical research institutions -- Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Medical College of Cornell University -- has announced the first wave of stem cell research projects to be funded through a $50 million gift from The Starr Foundation.

… Monday, July 31, 2006 First Research Projects to be Funded under the Tri-Institutional Stem Cell Initiative The Tri-Institutional Stem Cell Initiative , comprised of three leading New York City biomedical research institutions — Memorial Sloan Kettering Cancer Center, The Rockefeller University, and

A collaborative team from MSK has uncovered important new findings that explain why ovarian cancer does not respond to immunotherapy.

… Wednesday, December 14, 2022 A team at Memorial Sloan Kettering Cancer Center (MSK) has uncovered several mechanisms of immune escape that can help explain why ovarian cancers have been resistant to immunotherapy to date. The researchers found that ovarian cancer is even more complex than previously

Two of the year's top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan Kettering investigators.

… Monday, February 6, 2012 Summary Two of the year’s top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan Kettering investigators. Two of the top five advances in cancer research for 2011 cited by the annual progress report of the American Society

Clinicians and scientists at MSK continue to investigate new ways to improve outcomes for patients with thyroid cancer. Recent research insights from MSK thyroid cancer experts include, the safety and feasibility of active surveillance for certain patients, the identification of mutation profiles of subgroups, recommendations for future clinical trials of redifferentiation therapy, and study results showing that larotrectinib may be beneficial for treatment-naïve patients with NTRK fusion-positive thyroid cancer.

… Thursday, July 10, 2025 Clinicians and scientists at Memorial Sloan Kettering Cancer Center (MSK) continue to investigate new ways to improve outcomes for patients with thyroid cancer. Recent research insights from MSK thyroid cancer experts include: the safety and feasibility of active surveillance

Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab and ipilimumab or nivolumab alone significantly increases progression-free survival over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering simultaneously presented today at the American Society of Clinical Oncology annual meeting and published online in the New England Journal of Medicine.

… Sunday, May 31, 2015 Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers

Memorial Sloan Kettering researchers have found a way to restore innate immune defense in the intestines and enhance resistance to a potentially harmful antibiotic-resistant bacterium.

… Monday, December 1, 2008 Summary Memorial Sloan Kettering researchers have found a way to restore innate immune defense in the intestines and enhance resistance to a potentially harmful antibiotic-resistant bacterium. Infection by antibiotic-resistant bacteria is a dangerous complication of broad-spectrum

Computational biologist Thomas Norman, PhD, of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named one of 53 recipients of the prestigious 2020 National Institutes of Health (NIH) Director’s New Innovator Award. As part of the award, Dr. Norman will receive $1.5 million in direct costs upfront in the first year of a five-year award. 

… Tuesday, October 6, 2020 Computational biologist  Thomas Norman, PhD , of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named one of 53 recipients of the prestigious 2020 National Institutes of Health (NIH) Director’s New Innovator Award. As part of the award, Dr. Norman will

Kravis WiSE promotes gender equity in science by providing stable funding and professional support for women in science at Memorial Sloan Kettering Cancer Center.

… Wednesday, March 6, 2024 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce four  Sloan Kettering Institute  (SKI) researchers have been named 2024  Marie-Josée Kravis WISE  fellowship grant recipients. Kravis WiSE was established in 2020, and is now in its fifth class. Kravis WISE remains